Study of iruplinalkib plus bevacizumab for ALK-positive lung cancer
This study tests a combination of two targeted medicines for people with a specific type of non-small cell lung cancer (NSCLC) that has the ALK gene change. The goal is to see if giving these drugs before surgery can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with non-small cell lung cancer (NSCLC) that has the ALK gene change.
- Your cancer is at stage II or III (has not spread far from the lung).
- You are between 18 and 80 years old.
- You have not had previous treatment with targeted therapy, immunotherapy, or other investigational drugs for your lung cancer.
- You are generally healthy enough to perform daily activities (ECOG performance status 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with alk-positive non-small cell lung cancer who are taking iruplinalkib to see how well it works and how safe it is in real life. It helps doctors learn more about the drug's effects outside of clinical trials.
This study tests whether taking a pill called iruplinalkib after surgery for early-stage ALK-positive lung cancer can help keep cancer from coming back. Iruplinalkib is a type of targeted therapy that blocks cancer cells with a specific ALK gene change.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This study looks at whether giving a targeted therapy pill (lorlatinib) before surgery can help shrink ALK-positive lung cancer and improve outcomes. It also aims to understand why some tumors may not respond to this treatment.
This trial tests a new combination of radiation, two immunotherapy drugs, and chemotherapy given before surgery for non-small-cell lung cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients with stage II-III disease that can be removed with surgery.
This trial tests a combination of an immunotherapy drug (Rilpufan α) with chemotherapy given before surgery for early-stage (stage II-III) non-small cell lung cancer. The goal is to shrink the tumor to make surgery more effective and potentially improve long-term outcomes.
Hear when a new ALK trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.